Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes.

Transplantation

Rajaei B, Roelofsen AL, Shokrollahi E, Brinkhof B, Naumovska E, van der Sluis RJ, Nieveen M, Engelse M, de Koning E, Carlotti F.
PMID: 34908335
Transplantation. 2021 Dec 01;105(12):S26. doi: 10.1097/01.tp.0000804432.75585.bf.

No abstract available.

Cite
Rajaei B, Roelofsen AL, Shokrollahi E, et al. 402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes. Transplantation. 2021;105(12):S26doi: 10.1097/01.tp.0000804432.75585.bf.
Rajaei, B., Roelofsen, A. L., Shokrollahi, E., Brinkhof, B., Naumovska, E., van der Sluis, R. J., Nieveen, M., Engelse, M., de Koning, E., & Carlotti, F. (2021). 402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes. Transplantation, 105(12), S26. https://doi.org/10.1097/01.tp.0000804432.75585.bf
Rajaei, Bahareh, et al. "402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes." Transplantation vol. 105,12 (2021): S26. doi: https://doi.org/10.1097/01.tp.0000804432.75585.bf
Rajaei B, Roelofsen AL, Shokrollahi E, Brinkhof B, Naumovska E, van der Sluis RJ, Nieveen M, Engelse M, de Koning E, Carlotti F. 402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes. Transplantation. 2021 Dec 01;105(12):S26. doi: 10.1097/01.tp.0000804432.75585.bf. PMID: 34908335.
Copy Download .nbib Format: NLM
402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes.

Transplantation

Rajaei B, Roelofsen AL, Shokrollahi E, Brinkhof B, Naumovska E, van der Sluis RJ, Nieveen M, Engelse M, de Koning E, Carlotti F.
PMID: 34908335
Transplantation. 2021 Dec 01;105(12):S26. doi: 10.1097/01.tp.0000804432.75585.bf.

No abstract available.

Cite
Rajaei B, Roelofsen AL, Shokrollahi E, et al. 402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes. Transplantation. 2021;105(12):S26doi: 10.1097/01.tp.0000804432.75585.bf.
Rajaei, B., Roelofsen, A. L., Shokrollahi, E., Brinkhof, B., Naumovska, E., van der Sluis, R. J., Nieveen, M., Engelse, M., de Koning, E., & Carlotti, F. (2021). 402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes. Transplantation, 105(12), S26. https://doi.org/10.1097/01.tp.0000804432.75585.bf
Rajaei, Bahareh, et al. "402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes." Transplantation vol. 105,12 (2021): S26. doi: https://doi.org/10.1097/01.tp.0000804432.75585.bf
Rajaei B, Roelofsen AL, Shokrollahi E, Brinkhof B, Naumovska E, van der Sluis RJ, Nieveen M, Engelse M, de Koning E, Carlotti F. 402.1: Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes. Transplantation. 2021 Dec 01;105(12):S26. doi: 10.1097/01.tp.0000804432.75585.bf. PMID: 34908335.
Copy Download .nbib Format: NLM
Human monoclonal antibodies against .

eLife

de Vor L, van Dijk B, van Kessel K, Kavanaugh JS, de Haas C, Aerts PC, Viveen MC, Boel EC, Fluit AC, Kwiecinski JM, Krijger GC, Ramakers RM, Beekman FJ, Dadachova E, Lam MG, Vogely HC, van der Wal BC, van Strijp JA, Horswill AR, Weinans H, Rooijakkers SH.
PMID: 34989676
Elife. 2022 Jan 06;11. doi: 10.7554/eLife.67301.

Implant-associated

Cite
de Vor L, van Dijk B, van Kessel K, et al. Human monoclonal antibodies against . Elife. 2022;11doi: 10.7554/eLife.67301.
de Vor, L., van Dijk, B., van Kessel, K., Kavanaugh, J. S., de Haas, C., Aerts, P. C., Viveen, M. C., Boel, E. C., Fluit, A. C., Kwiecinski, J. M., Krijger, G. C., Ramakers, R. M., Beekman, F. J., Dadachova, E., Lam, M. G., Vogely, H. C., van der Wal, B. C., van Strijp, J. A., Horswill, A. R., Weinans, H., & Rooijakkers, S. H. (2022). Human monoclonal antibodies against . eLife, 11. https://doi.org/10.7554/eLife.67301
de Vor, Lisanne, et al. "Human monoclonal antibodies against ." eLife vol. 11 (2022). doi: https://doi.org/10.7554/eLife.67301
de Vor L, van Dijk B, van Kessel K, Kavanaugh JS, de Haas C, Aerts PC, Viveen MC, Boel EC, Fluit AC, Kwiecinski JM, Krijger GC, Ramakers RM, Beekman FJ, Dadachova E, Lam MG, Vogely HC, van der Wal BC, van Strijp JA, Horswill AR, Weinans H, Rooijakkers SH. Human monoclonal antibodies against . Elife. 2022 Jan 06;11. doi: 10.7554/eLife.67301. PMID: 34989676.
Copy Download .nbib Format: NLM
Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

Oncogenesis

Heijkants RC, Nieveen M, Hart KC', Teunisse AFAS, Jochemsen AG.
PMID: 29593251
Oncogenesis. 2018 Mar 29;7(3):33. doi: 10.1038/s41389-018-0041-y.

Uveal melanoma (UM) is the most frequent ocular cancer in adults, accounting for ~5% of the total melanoma incidence. Although the primary tumor is well treatable, patients frequently develop metastases for which no curative therapy exists. Highly activated protein...

Cite
Heijkants RC, Nieveen M, Hart KC', et al. Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies. Oncogenesis. 2018;7(3):33doi: 10.1038/s41389-018-0041-y.
Heijkants, R. C., Nieveen, M., Hart, K. C. '., Teunisse, A. F. A. S., & Jochemsen, A. G. (2018). Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies. Oncogenesis, 7(3), 33. https://doi.org/10.1038/s41389-018-0041-y
Heijkants, R C, et al. "Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies." Oncogenesis vol. 7,3 (2018): 33. doi: https://doi.org/10.1038/s41389-018-0041-y
Heijkants RC, Nieveen M, Hart KC', Teunisse AFAS, Jochemsen AG. Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies. Oncogenesis. 2018 Mar 29;7(3):33. doi: 10.1038/s41389-018-0041-y. PMID: 29593251; PMCID: PMC5874255.
Copy Download .nbib Format: NLM
Human monoclonal antibodies against .

eLife

de Vor L, van Dijk B, van Kessel K, Kavanaugh JS, de Haas C, Aerts PC, Viveen MC, Boel EC, Fluit AC, Kwiecinski JM, Krijger GC, Ramakers RM, Beekman FJ, Dadachova E, Lam MG, Vogely HC, van der Wal BC, van Strijp JA, Horswill AR, Weinans H, Rooijakkers SH.
PMID: 34989676
Elife. 2022 Jan 06;11. doi: 10.7554/eLife.67301.

Implant-associated

Cite
de Vor L, van Dijk B, van Kessel K, et al. Human monoclonal antibodies against . Elife. 2022;11doi: 10.7554/eLife.67301.
de Vor, L., van Dijk, B., van Kessel, K., Kavanaugh, J. S., de Haas, C., Aerts, P. C., Viveen, M. C., Boel, E. C., Fluit, A. C., Kwiecinski, J. M., Krijger, G. C., Ramakers, R. M., Beekman, F. J., Dadachova, E., Lam, M. G., Vogely, H. C., van der Wal, B. C., van Strijp, J. A., Horswill, A. R., Weinans, H., & Rooijakkers, S. H. (2022). Human monoclonal antibodies against . eLife, 11. https://doi.org/10.7554/eLife.67301
de Vor, Lisanne, et al. "Human monoclonal antibodies against ." eLife vol. 11 (2022). doi: https://doi.org/10.7554/eLife.67301
de Vor L, van Dijk B, van Kessel K, Kavanaugh JS, de Haas C, Aerts PC, Viveen MC, Boel EC, Fluit AC, Kwiecinski JM, Krijger GC, Ramakers RM, Beekman FJ, Dadachova E, Lam MG, Vogely HC, van der Wal BC, van Strijp JA, Horswill AR, Weinans H, Rooijakkers SH. Human monoclonal antibodies against . Elife. 2022 Jan 06;11. doi: 10.7554/eLife.67301. PMID: 34989676; PMCID: PMC8751199.
Copy Download .nbib Format: NLM
Human monoclonal antibodies against .

eLife

de Vor L, van Dijk B, van Kessel K, Kavanaugh JS, de Haas C, Aerts PC, Viveen MC, Boel EC, Fluit AC, Kwiecinski JM, Krijger GC, Ramakers RM, Beekman FJ, Dadachova E, Lam MG, Vogely HC, van der Wal BC, van Strijp JA, Horswill AR, Weinans H, Rooijakkers SH.
PMID: 34989676
Elife. 2022 Jan 06;11. doi: 10.7554/eLife.67301.

Implant-associated

Cite
de Vor L, van Dijk B, van Kessel K, et al. Human monoclonal antibodies against . Elife. 2022;11doi: 10.7554/eLife.67301.
de Vor, L., van Dijk, B., van Kessel, K., Kavanaugh, J. S., de Haas, C., Aerts, P. C., Viveen, M. C., Boel, E. C., Fluit, A. C., Kwiecinski, J. M., Krijger, G. C., Ramakers, R. M., Beekman, F. J., Dadachova, E., Lam, M. G., Vogely, H. C., van der Wal, B. C., van Strijp, J. A., Horswill, A. R., Weinans, H., & Rooijakkers, S. H. (2022). Human monoclonal antibodies against . eLife, 11. https://doi.org/10.7554/eLife.67301
de Vor, Lisanne, et al. "Human monoclonal antibodies against ." eLife vol. 11 (2022). doi: https://doi.org/10.7554/eLife.67301
de Vor L, van Dijk B, van Kessel K, Kavanaugh JS, de Haas C, Aerts PC, Viveen MC, Boel EC, Fluit AC, Kwiecinski JM, Krijger GC, Ramakers RM, Beekman FJ, Dadachova E, Lam MG, Vogely HC, van der Wal BC, van Strijp JA, Horswill AR, Weinans H, Rooijakkers SH. Human monoclonal antibodies against . Elife. 2022 Jan 06;11. doi: 10.7554/eLife.67301. PMID: 34989676; PMCID: PMC8751199.
Copy Download .nbib Format: NLM
Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.

Oncotarget

Heijkants R, Willekens K, Schoonderwoerd M, Teunisse A, Nieveen M, Radaelli E, Hawinkels L, Marine JC, Jochemsen A.
PMID: 29464063
Oncotarget. 2017 Dec 15;9(5):6174-6187. doi: 10.18632/oncotarget.23485. eCollection 2018 Jan 19.

Very little to no improvement in overall survival has been seen in patients with advanced non-resectable cutaneous melanoma or metastatic uveal melanoma in decades, highlighting the need for novel therapeutic options. In this study we investigated as a potential...

Cite
Heijkants R, Willekens K, Schoonderwoerd M, et al. Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma. Oncotarget. 2017;9(5):6174-6187doi: 10.18632/oncotarget.23485.
Heijkants, R., Willekens, K., Schoonderwoerd, M., Teunisse, A., Nieveen, M., Radaelli, E., Hawinkels, L., Marine, J. C., & Jochemsen, A. (2018). Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma. Oncotarget, 9(5), 6174-6187. https://doi.org/10.18632/oncotarget.23485
Heijkants, Renier, et al. "Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma." Oncotarget vol. 9,5 (2018): 6174-6187. doi: https://doi.org/10.18632/oncotarget.23485
Heijkants R, Willekens K, Schoonderwoerd M, Teunisse A, Nieveen M, Radaelli E, Hawinkels L, Marine JC, Jochemsen A. Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma. Oncotarget. 2017 Dec 15;9(5):6174-6187. doi: 10.18632/oncotarget.23485. eCollection 2018 Jan 19. PMID: 29464063; PMCID: PMC5814203.
Copy Download .nbib Format: NLM
Human monoclonal antibodies against .

eLife

de Vor L, van Dijk B, van Kessel K, Kavanaugh JS, de Haas C, Aerts PC, Viveen MC, Boel EC, Fluit AC, Kwiecinski JM, Krijger GC, Ramakers RM, Beekman FJ, Dadachova E, Lam MG, Vogely HC, van der Wal BC, van Strijp JA, Horswill AR, Weinans H, Rooijakkers SH.
PMID: 34989676
Elife. 2022 Jan 06;11. doi: 10.7554/eLife.67301.

Implant-associated

Cite
de Vor L, van Dijk B, van Kessel K, et al. Human monoclonal antibodies against . Elife. 2022;11doi: 10.7554/eLife.67301.
de Vor, L., van Dijk, B., van Kessel, K., Kavanaugh, J. S., de Haas, C., Aerts, P. C., Viveen, M. C., Boel, E. C., Fluit, A. C., Kwiecinski, J. M., Krijger, G. C., Ramakers, R. M., Beekman, F. J., Dadachova, E., Lam, M. G., Vogely, H. C., van der Wal, B. C., van Strijp, J. A., Horswill, A. R., Weinans, H., & Rooijakkers, S. H. (2022). Human monoclonal antibodies against . eLife, 11. https://doi.org/10.7554/eLife.67301
de Vor, Lisanne, et al. "Human monoclonal antibodies against ." eLife vol. 11 (2022). doi: https://doi.org/10.7554/eLife.67301
de Vor L, van Dijk B, van Kessel K, Kavanaugh JS, de Haas C, Aerts PC, Viveen MC, Boel EC, Fluit AC, Kwiecinski JM, Krijger GC, Ramakers RM, Beekman FJ, Dadachova E, Lam MG, Vogely HC, van der Wal BC, van Strijp JA, Horswill AR, Weinans H, Rooijakkers SH. Human monoclonal antibodies against . Elife. 2022 Jan 06;11. doi: 10.7554/eLife.67301. PMID: 34989676.
Copy Download .nbib Format: NLM
Rapid and simple isolation of pure photosystem II core and reaction center particles from spinach.

Photosynthesis research

van Leeuwen PJ, Nieveen MC, van de Meent EJ, Dekker JP, van Gorkom HJ.
PMID: 24414974
Photosynth Res. 1991 Jun;28(3):149-53. doi: 10.1007/BF00054128.

Pure and active oxygen-evolving PS II core particles containing 35 Chl per reaction center were isolated with 75% yield from spinach PS II membrane fragments by incubation with n-dodecyl-β-D-maltoside and a rapid one step anion-exchange separation. By Triton X-100...

Cite
van Leeuwen PJ, Nieveen MC, van de Meent EJ, et al. Rapid and simple isolation of pure photosystem II core and reaction center particles from spinach. Photosynth Res. 1991;28(3):149-53doi: 10.1007/BF00054128.
van Leeuwen, P. J., Nieveen, M. C., van de Meent, E. J., Dekker, J. P., & van Gorkom, H. J. (1991). Rapid and simple isolation of pure photosystem II core and reaction center particles from spinach. Photosynthesis research, 28(3), 149-53. https://doi.org/10.1007/BF00054128
van Leeuwen, P J, et al. "Rapid and simple isolation of pure photosystem II core and reaction center particles from spinach." Photosynthesis research vol. 28,3 (1991): 149-53. doi: https://doi.org/10.1007/BF00054128
van Leeuwen PJ, Nieveen MC, van de Meent EJ, Dekker JP, van Gorkom HJ. Rapid and simple isolation of pure photosystem II core and reaction center particles from spinach. Photosynth Res. 1991 Jun;28(3):149-53. doi: 10.1007/BF00054128. PMID: 24414974.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries